Osaic Holdings’s Gain Therapeutics GANX Stock Holding History

Osaic Holdings’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2,000	Closed	-$4.06K	–	8128
2026 Q2	$4.06K	Buy	+2,000	New	+$3.69K	﹤0.01%	7029
2024 Q1	–	Sell	-10,000	Closed	-$32.6K	–	7272
2023 Q4	$32.6K	Hold	10,000	–	–	﹤0.01%	5183
2023 Q3	$32.8K	Hold	10,000	–	–	﹤0.01%	5268
2023 Q2	$44.8K	Hold	10,000	–	–	﹤0.01%	5009
2023 Q1	$48.2K	Hold	10,000	–	–	﹤0.01%	4976
2022 Q4	$31K	Hold	10,000	–	–	﹤0.01%	5272
2022 Q3	$33K	Sell	10,000 -100	-1%	-$376	﹤0.01%	5234
2022 Q2	$36K	Buy	10,100 +50	+0.5%	+$172	﹤0.01%	5192
2022 Q1	$41K	Hold	10,050	–	–	﹤0.01%	5233
2021 Q4	$54K	Buy	+10,050	New	+$69.3K	﹤0.01%	5087

Other funds holding GANX

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

PCM

Potomac Capital Management New York $129M AUM 50.83% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Osaic Holdings's GANX Position: Q3 2026 in Review

Osaic Holdings sold out of Gain Therapeutics (GANX) in Q3 2026, closing a stake of 2,000 shares — an estimated $4.06K sold.

Osaic Holdings first reported a position in GANX in Q4 2021 and held it in 10 quarters. The position peaked at $54K in Q4 2021. 38 funds tracked by Wall St. Rank hold GANX as of Q3 2026.

Osaic Holdings reported no remaining Gain Therapeutics position as of Q3 2026 after selling out during the quarter.
Osaic Holdings sold 2,000 Gain Therapeutics shares in Q3 2026, an estimated $4.06K.
Osaic Holdings first reported a position in Gain Therapeutics in Q4 2021 and held it in 10 quarters.
Osaic Holdings's Gain Therapeutics position peaked at $54K in Q4 2021.
38 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.

Based on Osaic Holdings's 13F filing for Q3 2026, filed 12 Nov 2026.